JNJ

227.89

+0.1%↑

ISRG

506.12

-3%↓

ABT

106.04

-0.09%↓

MDT

101.08

+0.4%↑

A

132.72

-0.98%↓

JNJ

227.89

+0.1%↑

ISRG

506.12

-3%↓

ABT

106.04

-0.09%↓

MDT

101.08

+0.4%↑

A

132.72

-0.98%↓

JNJ

227.89

+0.1%↑

ISRG

506.12

-3%↓

ABT

106.04

-0.09%↓

MDT

101.08

+0.4%↑

A

132.72

-0.98%↓

JNJ

227.89

+0.1%↑

ISRG

506.12

-3%↓

ABT

106.04

-0.09%↓

MDT

101.08

+0.4%↑

A

132.72

-0.98%↓

JNJ

227.89

+0.1%↑

ISRG

506.12

-3%↓

ABT

106.04

-0.09%↓

MDT

101.08

+0.4%↑

A

132.72

-0.98%↓

Search

Maravai LifeSciences Holdings Inc (Class A)

Ouvert

3.43

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.34

Max

3.52

Chiffres clés

By Trading Economics

Revenu

44M

-26M

Ventes

-5.8M

42M

Marge bénéficiaire

-61.388

Employés

550

EBITDA

44M

-22M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+24.27% upside

Dividendes

By Dow Jones

Prochains Résultats

17 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

279M

1.4B

Ouverture précédente

3.43

Clôture précédente

3.43

Score Technique

By Trading Central

Confiance

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

28 janv. 2026, 23:51 UTC

Résultats

Correction to Samsung Fourth-Quarter Net Profit Article

28 janv. 2026, 23:49 UTC

Actions en Tendance

Stocks to Watch: Meta, IBM, Las Vegas Sands, Whirlpool

28 janv. 2026, 23:19 UTC

Résultats

Samsung's Fourth-Quarter Net Profit Beats Consensus

28 janv. 2026, 22:43 UTC

Résultats

Waste Management Logs Higher 4Q Profit as Revenue Rises

29 janv. 2026, 00:00 UTC

Acquisitions, Fusions, Rachats

Diller's Overture Came Before Warner Unveiled Split Plans, Source Says -- WSJ

29 janv. 2026, 00:00 UTC

Acquisitions, Fusions, Rachats

Warner Says CNN Wasn't and Isn't for Sale -- WSJ

29 janv. 2026, 00:00 UTC

Acquisitions, Fusions, Rachats

Barry Diller Told Warner Bros. Discovery He Is Interested in Buying CNN -- WSJ

29 janv. 2026, 00:00 UTC

Acquisitions, Fusions, Rachats

Barry Diller Approached Warner Bros. Discovery Last Year About Buying CNN, Sources Say -- WSJ

28 janv. 2026, 23:49 UTC

Market Talk

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

28 janv. 2026, 23:30 UTC

Market Talk

Tesla to Use Car Factory for Robot Aims -- Market Talk

28 janv. 2026, 23:28 UTC

Résultats

Microsoft's Earnings Surge, Elevated by Cloud Business -- 3rd Update

28 janv. 2026, 23:26 UTC

Résultats

Meta Reports Record Sales, Massive Spending Hike on AI Buildout -- 2nd Update

28 janv. 2026, 23:21 UTC

Résultats

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 janv. 2026, 23:18 UTC

Résultats
Acquisitions, Fusions, Rachats

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 janv. 2026, 22:58 UTC

Résultats

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 janv. 2026, 22:48 UTC

Market Talk

Woodside Energy Has Form With Conservative Production Guidance -- Market Talk

28 janv. 2026, 22:45 UTC

Résultats

Samsung Electronics 2025 Net KRW45.207T Vs. Net KRW34.451T >005930.SE

28 janv. 2026, 22:44 UTC

Résultats

Samsung Electronics 2025 Oper Pft KRW43.601T Vs. Pft KRW32.726T >005930.SE

28 janv. 2026, 22:43 UTC

Résultats

Samsung Electronics 2025 Rev KRW333.606T Vs. KRW300.871T >005930.SE

28 janv. 2026, 22:41 UTC

Résultats
Actions en Tendance

Earnings in Focus Wednesday: Microsoft, Tesla, Meta, Starbucks -- WSJ

28 janv. 2026, 22:41 UTC

Market Talk

Rising AUD Typically Sees Australian Stocks Outperform -- Market Talk

28 janv. 2026, 22:41 UTC

Résultats

Meta Stock Rises on Strong Earnings. Expenses Are Mounting. -- Barrons.com

28 janv. 2026, 22:40 UTC

Résultats

Samsung Electronics 4Q Net Profit Beat FactSet-Compiled Consensus

28 janv. 2026, 22:39 UTC

Résultats

Samsung Electronics 4Q Net KRW19.642T Vs. Net KRW7.754T >005930.SE

28 janv. 2026, 22:38 UTC

Résultats

Samsung Electronics 4Q Oper Pft KRW20.074T Vs. Pft KRW6.493T >005930.SE

28 janv. 2026, 22:37 UTC

Résultats

Samsung Electronics 4Q Rev KRW93.837T Vs. KRW75.788T >005930.SE

28 janv. 2026, 22:35 UTC

Résultats

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 janv. 2026, 22:26 UTC

Market Talk
Résultats

Meta's Rising CapEx is Fueled by High Pay for AI Workers -- Market Talk

28 janv. 2026, 22:20 UTC

Market Talk

Global Equities Roundup: Market Talk

28 janv. 2026, 22:20 UTC

Market Talk

Woodside Energy's Oil Assets Blamed for Guidance Miss -- Market Talk

Comparaison

Variation de prix

Maravai LifeSciences Holdings Inc (Class A) prévision

Objectif de Prix

By TipRanks

24.27% hausse

Prévisions sur 12 Mois

Moyen 4.25 USD  24.27%

Haut 4.5 USD

Bas 4 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

3

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

2.02 / 2.115Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat